BELLUS Health Inc. (BLU)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 8.10 |
| Open | 8.10 |
| Bid | 8.28 x 1000 |
| Ask | 8.50 x 1000 |
| Day's Range | 8.10 - 8.39 |
| 52 Week Range | 2.60 - 9.84 |
| Volume | |
| Avg. Volume | 813,980 |
| Market Cap | 888.143M |
| Beta (5Y Monthly) | -0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.81 |
| Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.09 |
- Zacks
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
- Zacks
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
- Zacks
Vertex (VRTX) Kidney Drug Gets FDA Breakthrough Designation
Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.
© 2022 Yahoo. All rights reserved.
